NEW YORK, May 22, 2006 (PRIMEZONE) -- Enhance Biotech, Inc. (Pink Sheets:EBOI), a company developing a portfolio of products focused on lifestyle drugs, announced today that it has sold its opioid Delta receptor compound portfolio to Mount Cook Biosciences Inc., a company formed and funded by Paramount Biosciences, LLC of New York. The portfolio sold to Mount Cook Biosciences includes two clinical stage compounds and a library of pre-clinical compounds. The lead compound, DPI-125 is a novel mixed delta/mu opioid receptor agonist, which is being developed for the treatment of pain. A second compound, DPI-221 is intended to address urge and mixed urinary incontinence, and recently received IND approval. The portfolio also includes Enhance’s pre-clinical Delta receptor programs in Parkinson’s disease, Depression, Cardio Protection and Premature Ejaculation which will continue to be developed by Mount Cook Biosciences.
